Pleural Diseases

  • Samuel P. Hammar


Vertebrates have a complex system of body cavities of mesodermal origin called the pleural, pericardial, and peritoneal cavities. These cavities are lined by a flattened layer of cells referred to as mesothelium, and are referred to as serous cavities. Embryologically, the cavities develop from the coelomic cavity, which develops early in embryogenesis.1 The lung buds initially grow into what is referred to as the pericardial-peritoneal cavity, which later develops into the pleural-pericardial cavity. The pleural-pericardial membrane separates the pleural cavity from the pericardial cavity, and the pleural-peritoneal membrane separates the pleural cavity from the peritoneal cavity (Fig. 34-1). An excellent description of the development of the coelomic cavity was published in 1890.2 In the adult, the pleura is divided into the parietal pleura, which lines the inside of the thoracic cavity, and the visceral pleura, which covers the lung parenchyma (Fig. 34-2). The visceral and parietal pleura are connected at the hilum of the lung.


Mesothelial Cell Pleural Fluid Malignant Pleural Mesothelioma Malignant Mesothelioma Asbestos Exposure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Davies J. Development of the respiratory system. In: Human developmental anatomy. New York: Ronald Press, 1963: 135–143.Google Scholar
  2. 2.
    Minot C. The mesoderm and the coelom of vertebrates. Am Nat 1890; 24: 877–898.CrossRefGoogle Scholar
  3. 3.
    Sahn SA. The pleura. Am Rev Respir Dis 1988; 138: 184–234.CrossRefGoogle Scholar
  4. 4.
    Light RW. Anatomy of the pleura. In: Pleural diseases. 2d Ed. Philadelphia: Lea & Febiger, 1990: 1–7.Google Scholar
  5. 5.
    Antony VB, Sahn SA, Mossman B, Gail DB, Kalica A. Pleural cell biology in health and disease. Am Rev Respir Dis 1992; 145: 1236–1239.PubMedCrossRefGoogle Scholar
  6. 6.
    Gaudio E, Rendina E, Pannarale L, Ricci C, Marinozzi G. Surface morphology of the human pleura: A scanning electron microscopic study. Chest 1988; 92: 149153.Google Scholar
  7. 7.
    Wang NS. The preformed stomas connecting the pleural cavity and lymphatics in the parietal pleura. Am Rev Respir Dis 1975; 111: 12–20.PubMedGoogle Scholar
  8. 8.
    Leak LV, Rahil L. Permeability of the diaphragmatic mesothelium: The ultrastructural basis for “stomata. ” Am J Anat 1978; 151: 557–594.PubMedCrossRefGoogle Scholar
  9. 9.
    Courtice FC, Simmonds SJ. Physiological significance of lymph drainage of the serous cavities and lungs. Physiol Rev 1954; 34: 419–448.PubMedGoogle Scholar
  10. 10.
    Sahn SA. The differential diagnosis of pleural effusions. West J Med 1982; 137: 99–108.PubMedGoogle Scholar
  11. 11.
    Pistolesi M, Miniati M, Giontini C. Pleural liquid and solute exchange. Am Rev Respir Dis 1989; 140: 825847.Google Scholar
  12. 12.
    Light RW. Clinical manifestations and useful tests. Pleural diseases. 2d Ed. Philaelphia: Lea & Febiger, 1990: 39–73.Google Scholar
  13. 13.
    Yokoi T, Mark EJ. Atypical mesothelial hyperplasia associated with bronchogenic carcinoma. Hum Pathol 1991; 22: 695–699.PubMedCrossRefGoogle Scholar
  14. 14.
    Buchanan DR, Johnston IP, Ken IH, Hetzel MR, Cor-rin B, Turner-Warwick M. Cryptogenic bilateral fibrosing pleuritis. Br J Dis Chest 1988; 82: 186–193.PubMedCrossRefGoogle Scholar
  15. 15.
    Askin FB, McCann BC, Kuhn C. Reactive eosinophilic pleuritis: A lesion to be distinguished from pulmonary eosinophilic granuloma. Arch Pathol Lab Med 1977; 101: 187–191.PubMedGoogle Scholar
  16. 16.
    Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic effusions. Am J Med 1980; 985–986.Google Scholar
  17. 17.
    Taryle DA, Potts DE, Sahn SA. The incidence and clinical correlates of parapneumonic effusions in pneumococcal pneumonia. Chest 1978; 74: 170–173.PubMedCrossRefGoogle Scholar
  18. 18.
    Bartlett JG, Gorbach SL, Thadepalli H, Finegold SM. Bacteriology of empyema. Lancet 1974;i:338–340.Google Scholar
  19. 19.
    Varkey B, Rose HD, Kutty CPK, Politis J. Empyema thoracis during a ten-year period. Arch Intern Med 1981; 141: 1771–1776.PubMedCrossRefGoogle Scholar
  20. 20.
    United States Department of Health Education and Welfare, Public Health Service. Center for Disease Control. Extrapulmonary tuberculosis in the United States. DHEW Publication (CDC) 78–8360. Washington, DC, 1978.Google Scholar
  21. 21.
    Stead WW, Eichenholz A, Stauss HK. Operative and pathologic -findings in twenty-four patients with syndrome of idiopathic pleurisy with effusion, presumably tuberculosis. Am Rev Tuberc 1955; 71: 473–502.PubMedGoogle Scholar
  22. 22.
    Abrams WB, Small MJ. Current concepts of tuberculous pleurisy with effusion as derived from pleural biopsy studies. Scand J Respir Dis 1960; 38: 60–65.Google Scholar
  23. 23.
    Green WR, Bouchette D. Pleural mucormycosis (zyomycosis). Arch Pathol Lab Med 1986; 110: 441–442.PubMedGoogle Scholar
  24. 24.
    Mariuz P, Raviglione MC, Gould IA, Mollen MP. Pleural pneumocystis carinii infection. Chest 1991; 99: 774776.Google Scholar
  25. 25.
    Rubin EH. Pulmonary lesions in “rheumatoid disease” with remarks on diffuse interstitial fibrosis. Am J Med 1955; 19: 569–582.PubMedCrossRefGoogle Scholar
  26. 26.
    Sievers K, Aho K, Hurri L, Perttala Y. Studies of rheumatoid pulmonary disease: A comparison of roentgenographic findings among patients with high rheumatoid factor titers and with completely negative reactions. Acta Tuberc Scand 1964; 45: 21–34.Google Scholar
  27. 27.
    Walker WC, Wright V. Pulmonary lesions and rheumatoid arthritis. Medicine (Baltimore) 1968; 47: 501–519.CrossRefGoogle Scholar
  28. 28.
    Horler AR, Thompson M. The pleural and pulmonary complications of rheumatoid arthritis. Ann Intern Med 1959; 51: 1179–1203.PubMedCrossRefGoogle Scholar
  29. 29.
    Wilen SB, Rabinowitz JG, Ulrich S, Lyons HA. Pleural involvement in sarcoidosis. Am J Med 1974; 57: 200209.Google Scholar
  30. 30.
    Mark EJ, Matsubara O, Jan-Liu NS, Fineberg R. The pulmonary biopsy in the early diagnosis of Wegener’s (pathergic) granulomatosis: A study based on 35 open lung biopsies. Hum Pathol 1988; 19: 1065–1071.PubMedCrossRefGoogle Scholar
  31. 31.
    Gonzalez L, VanOrdstrand HS. Wegener’s granulomatosis. Radiology 1973; 107: 295–300.PubMedGoogle Scholar
  32. 32.
    Liem K, ten Veen JH, Lie KI, Feltkamp TEW, Durrer D. Incidence and significance of heart muscle antibodies in patients with acute myocardial infarction and unstable angina. Acta Med Scand 1979; 206: 473–475.PubMedCrossRefGoogle Scholar
  33. 33.
    Toole JC, Silverman ME. Pericarditis of acute myocardial infarction. Chest 1975; 67: 647–653.PubMedCrossRefGoogle Scholar
  34. 34.
    Engle MA, McCabe JC, Ebert PA, Zabriskie J. The post-cardiotomy syndrome and anti-heart antibodies. Circulation 1974; 49: 401–406.PubMedCrossRefGoogle Scholar
  35. 35.
    Van Der Geld H. Anti-heart antibodies in the postpericardiotomy and post-myocardial infarction syndromes. Lancet 1964; ii:617–621.Google Scholar
  36. 36.
    Aisner J, Wiernick PH. Malignant mesothelioma. Current status and future prospects. Chest 1978; 74: 438443.Google Scholar
  37. 37.
    Chahinian AP. Malignant mesothelioma. In: Holland JF, Frei E, III, eds. Cancer medicine. Philadelphia: Lea & Febiger, 1982: 1744–1751.Google Scholar
  38. 38.
    Wagner E. Das tuberkelahnliche lymphadenom. Arch Heilk 1870; 11: 495–525.Google Scholar
  39. 39.
    Robertson HE. “Endothelioma” of the pleura. Am J Cancer 1924;8:317–375.Google Scholar
  40. 40.
    Klemperer P, Rabin CB. Primary neoplasms of pleura: report of 5 cases. Arch Pathol 1931; 11: 385–412.Google Scholar
  41. 41.
    Stout AP, Murray MR. Localized pleural mesothelioma: investigation of its characteristics and histogenesis by the method of tissue culture. Arch Pathol 1942; 34: 951–964.Google Scholar
  42. 42.
    Foster EA, Ackerman LV. Localized mesotheliomas of the pleura: The pathologic evaluation of 18 cases. Am J Clin Pathol 1960; 34: 349–364.PubMedGoogle Scholar
  43. 43.
    Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma and asbestos exposure in North Western Cape Province. Br J Ind Med 1960; 17: 260–271.PubMedGoogle Scholar
  44. 44.
    Wagner JC. The discovery of the association between blue asbestos and mesotheliomas and the aftermath. Br J Ind Med 1991; 48: 399–403.PubMedGoogle Scholar
  45. 45.
    Wagner Jc. Asbestos and mesothelioma: A personal reminiscence. In: Henderson Dw, Shilkin Kb, Langlois Slp, Whitaker D, eds. Malignant mesothelioma. New York: Hemisphere, 1992: xvii-xxv.Google Scholar
  46. 46.
    Selikoff IJ, Churg J, Hammond EC. Relation between exposure to asbestos and mesothelioma. N Engl J Med 1965; 272: 560–565.PubMedCrossRefGoogle Scholar
  47. 47.
    Wedler HW, Uber den Lungenkrebs bei Asbestose. Dtsch Arch Klin Med 1943; 191: 189–209.Google Scholar
  48. 48.
    Wedler HW. Uber den Lungonkrebs bei Asbestose. Deutsch Med Wochenschr 1943; 69: 575–576.CrossRefGoogle Scholar
  49. 49.
    Merewether ERA. Annual Report of the Chief Inspector of Factories for the year 1947. His Majesty’s Stationery Office, London. 1949: 78–81.Google Scholar
  50. 50.
    Mallory TB, Castleman B, Parris EE. Case records of the Massachusetts General Hospital #33111. N Engl J Med 1947; 236: 407–412.CrossRefGoogle Scholar
  51. 51.
    Weiss A. Pleurakrbs bei Lungenasbestose, in vivo morphologisch Geishert. Medizienische 1953; 3: 93–94.Google Scholar
  52. 52.
    Leicher F Primarer deckzellen Tumor des Bauchtells bei Asbestose. Arch Gewerbepathol Gewerbehyg 1954; 13: 382–392.Google Scholar
  53. 53.
    Keal EE. Asbestosis and abdominal neoplasms. Lancet 1960;ii:1211–1216.Google Scholar
  54. 54.
    Goodwin MC. Diffuse mesotheliomas with comment on their relationship to localized fibrous mesotheliomas. Cancer (Philadelphia) 1967; 10: 298–319.CrossRefGoogle Scholar
  55. 55.
    Motley RL. The lid comes off. Trial 1980; 15: 21–24.Google Scholar
  56. 56.
    Brodeur P. Expendable Americans. New York: Viking, 1974.Google Scholar
  57. 57.
    Brodeur P. The asbestos industry on trial. I-A failure to warn. II-Discovery. III Judgement. IV-Bankruptcy. New Yorker 1985;61:49–52+ (Je 10); 45–48+ Qe 17); 37–41+(Je 24); 36–38+ Ul 1).Google Scholar
  58. 58.
    McDonald AD, Harper A, El Attar DA, McDonald JC. Epidemiology of primary malignant mesothelial tumors in Canada. Cancer (Philadelphia) 1970; 26: 914919.Google Scholar
  59. 59.
    Theriault GP, Grand-Bois L. Mesothelioma and asbestos in the province of Quebec, 1969–1972. Arch Environ Health 1978; 33: 15–19.PubMedGoogle Scholar
  60. 60.
    Biava PM, Ferri R, Spacal B, et al. Cancro de lovora a Trieste: II mesothelioma della pleura. Sapere 1976; 79: 41–45.Google Scholar
  61. 61.
    Greenberg M, Lloyd-Davies TA. Mesothelioma register 1967–1968. Br J Ind Med 1974; 31: 91–104.PubMedGoogle Scholar
  62. 62.
    McDonald AD, McDonald JC. Malignant mesothelioma in North America. Cancer (Philadelphia) 1980; 46: 1650–1656.CrossRefGoogle Scholar
  63. 63.
    Cutler SJ, Young JL. Third National Cancer Survey: Incidence data. Natl Cancer Inst Monogr 1975; 41: 442.Google Scholar
  64. 64.
    Bruckman L, Rubino RA, Christine B. Asbestos and mesothelioma incidence in Connecticut. J Air Pollut Control Assoc 1977; 27: 121–126.PubMedCrossRefGoogle Scholar
  65. 65.
    Churg A. Malignant mesothelioma in British Columbia in 1982. Cancer (Philadelphia) 1985; 55: 672–674.CrossRefGoogle Scholar
  66. 66.
    Ferguson D. Malignant mesothelioma-the rising epidemic. Med J Austral 1989; 150: 233–235.PubMedGoogle Scholar
  67. 67.
    McDonald JC, McDonald AD. Epidemiology of mesothelioma from estimated incidence. Prey Med 1977; 6: 426 446.Google Scholar
  68. 68.
    Hughes JM, Weill H. Asbestos exposure-quantitative assessment of risk. Am Rev Respir Dis 1986; 133: 5–13.PubMedGoogle Scholar
  69. 69.
    Selikoff IJ, Hammond EC, Seidman H. Mortality experience of insulation workers in the United States and Canada 1943–1976. Ann NY Acad Sci 1979; 330: 9 1116.Google Scholar
  70. 70.
    Huncharek M. Changing risk groups for malignant mesothelioma. Cancer (Philadelphia) 1992; 69: 2704 2711.Google Scholar
  71. 71.
    Wagner JC. Mesothelioma and mineral fibers. Cancer (Philadelphia) 1986; 57: 1905–1911.CrossRefGoogle Scholar
  72. 72.
    Rom WM, Lockey JE. Diffuse malignant mesothelioma: a review. West J Med 1982; 137: 548–554.PubMedGoogle Scholar
  73. 73.
    Legha SS, Muggia FM. Pleural mesothelioma: Clinical features and therapeutic implications. Ann Intern Med 1977; 87: 613–621.PubMedCrossRefGoogle Scholar
  74. 74.
    Borow M, Conston A, Livornese L, Schalet N. Mesothelioma following exposure to asbestos: A review of 72 cases. Chest 1973; 64: 641–646.PubMedCrossRefGoogle Scholar
  75. 75.
    Cochrane JC, Webster I. Mesothelioma in relation to asbestos fibre exposure. A review of 70 serial cases. S Afr Med J 1978; 54: 279–281.PubMedGoogle Scholar
  76. 76.
    Tagnon I, Blot WJ, Stroube RB, et al. Mesothelioma associated with the shipbuilding industry in coastal Virginia. Cancer Res 1980; 40: 3875–3879.PubMedGoogle Scholar
  77. 77.
    Whitwell F, Rawcliffe RM. Diffuse malignant pleural mesothelioma and asbestos exposure. Thorax 1971; 26: 6–22.PubMedCrossRefGoogle Scholar
  78. 78.
    Hammas SP. Mesothelioma. In: Sheppard MN, ed. Practical pulmonary pathology. Kent: Edward Arnold (in press).Google Scholar
  79. 79.
    Taylor RA, Johnson LP. Mesothelioma: Current perspectives. West J Med 1981; 134: 379–383.PubMedGoogle Scholar
  80. 80.
    Vogelzang NJ, Schultz SM, Iannucci AM, Kennedy BJ. Malignant mesothelioma: The University of Minnesoto experience. Cancer (Philadelphia) 1984; 53: 377–383.CrossRefGoogle Scholar
  81. 81.
    Newhouse ML, Thompson H. Mesothelioma of pleura and peritoneum following exposure to asbestos in the London area. Br J Ind Med 1965; 22: 261–269.PubMedGoogle Scholar
  82. 82.
    Peto J, Henderson Be, Pike Mc. Trends in mesothelioma in the United States and the forecast epidemic due to asbestos exposure during World War ii. In: Peto R, Schneiderman M, eds. Quantification of occupational cancer. Banbary Report 9. New York: Cold Spring Harbor Laboratory: 51–69.Google Scholar
  83. 83.
    Roggli VL, McGavran MH, Subach J, Sybers HD, Greenberg SD. Pulmonary asbestos body counts and electron probe analysis of asbestos body cores in patients with mesothelioma: A study of 25 cases. Cancer (Philadelphia) 1982; 50: 2423–2432.Google Scholar
  84. 84.
    Oels HC, Harrison EG, Carr DT, Bernatz PE. Diffuse malignant mesothelioma of the pleura: A review of 37 cases. Chest 1971;60:564 ‘170.Google Scholar
  85. 85.
    Brenner J, Sordillo PP, Magill GB, Golbey RB. Malignant mesothelioma of the pleura: review of 123 patients. Cancer (Philadelphia) 1982; 49: 2431–2435.CrossRefGoogle Scholar
  86. 86.
    Ratzer ER, Pool JL, Melamed MR. Pleural mesotheliomas: Clinical experiences with thirty-seven patients. Am J Radiol 1967; 99: 863–880.Google Scholar
  87. 87.
    Newhouse ML, Berry G. Patterns of mortality in asbestos factory workers in London. Ann NY Acad Sci 1979; 330: 53–60.PubMedCrossRefGoogle Scholar
  88. 88.
    Newhouse ML, Berry G. Predictions of mortality from mesothelial tumours in asbestos factory workers. Br J Ind Med 1976; 33: 147–151.PubMedGoogle Scholar
  89. 89.
    Epler GR, Gerlad MXF, Gaensler EA, Carrington CB. Asbestos-related disease from household exposure. Respiration 1980; 39: 229–240.PubMedCrossRefGoogle Scholar
  90. 90.
    Chen W, Mottet NK. Malignant mesothelioma with minimal asbestos exposure. Hum Pathol 1978; 9: 253258.Google Scholar
  91. 91.
    Anderson HA, Lils R, Daum SM, et al. Asbestosis among household contacts of asbestos factory workers. Am NY Acad Sci 1979; 330: 387–399.CrossRefGoogle Scholar
  92. 92.
    Vianna NJ, Polan AK. Non-occupational exposure to asbestos and malignant mesothelioma in females. Lancet 1978;i:1061–1063.Google Scholar
  93. 93.
    Kane MJ, Chahinian P, Holland JF. Malignant mesothelioma in young adults. Cancer (Philadelphia) 1990; 65: 1449–1455.CrossRefGoogle Scholar
  94. 94.
    Cazzadori A, Malesani F, Romeo L. Malignant pleural mesothelioma caused by non-occupational childhood exposure to asbestos. Br J Ind Med 1992; 49: 599.PubMedGoogle Scholar
  95. 95.
    Dodoli D, Del Nevo M, Fiumalbi C, et al. Environmental household exposure to asbestos and occurrence of pleural mesothelioma. Am J Ind Med 1992; 21: 68 1687.Google Scholar
  96. 96.
    Staunton MF, Wrench C. Mechanisms of mesothelioma induction with asbestos and fibrous glass. J Natl Cancer Inst 1972; 48: 797–821.Google Scholar
  97. 97.
    Stanton MF, Layord M, Tegeris A, et al. Relation of particle dimension to carcinogenicity in amphibole asbestos and other fibrous minerals. J Natl Cancer Inst 1981; 67: 965–975.PubMedGoogle Scholar
  98. 98.
    Gross P. Is short fibered asbestos dust a biological hazard? Arch Environ Health 1974; 29: 115–117.PubMedGoogle Scholar
  99. 99.
    Churg A, Wiggs B. Fiber size and number in amphibole asbestos-induced mesothelioma. Am J Pathol 1984; 115: 437–442.PubMedGoogle Scholar
  100. 100.
    Weiss W. Mortality of a cohort exposed to chrysotile asbestos. J Occup Med 1977; 19: 737–740.PubMedGoogle Scholar
  101. 101.
    McDonald JC, Liddell FDK, Gibbs GW, Eyssen GE, McDonald AD. Dust exposure and mortality in chrysotile mining, 1910–75. Br J Ind Med 1980; 37: 1124.Google Scholar
  102. 102.
    McDonald AD, Fry JS, Mesothelioma and fiber type in three American asbestos factories-preliminary report. Scand J Work Environ Health 1982; 8 (Suppl.): 55–58.Google Scholar
  103. 103.
    Acheson ED, Gardner MJ, Pippard EC, Grime LP. Mortality of two groups of women who manufactured gas masks from chrysotile and crocidolite asbestos: A 40-year follow-up. Br J Ind Med 1982; 39: 344–348.PubMedGoogle Scholar
  104. 104.
    Dement JM, Harris RL, Symons MJ, Shy CM. Exposure and mortality among chrysotile asbestos workers. Part II. Mortality. Am J Ind Med 1983; 4: 421–433.PubMedCrossRefGoogle Scholar
  105. 105.
    Browne K, Smither WJ. Asbestos related mesothelioma: Factors discriminating between pleural and peritoneal sites. Br J Ind Med 1983; 40: 145–152.PubMedGoogle Scholar
  106. 106.
    Berry G, Newhouse ML. Mortality of workers manufacturing friction materials using asbestos. Br J Ind Med 1983; 40: 1–7.PubMedGoogle Scholar
  107. 107.
    Acheson ED, Gardner MJ, Bennet C, Winter PD. Mesothelioma in a factory using amosite and chrysotile asbestos. Lancet 1981; ii: 1403–1406.Google Scholar
  108. 108.
    Churg A, Wiggs B, Depaoli L, Kampe B, Stevens B. Lung asbestos content in chrysotile workers with mesothelioma. Am Rev Respir Dis 1984; 130: 1042–1045.PubMedGoogle Scholar
  109. 109.
    Rogers AJ, Leigh J, Berry G, Ferguson DA, Mulder HB, Ackad M. Relationship between lung asbestos fiber type and concentration and relative risk of mesothelioma: A case-control study. Cancer (Philadelphia) 1991; 67: 1912–1920.CrossRefGoogle Scholar
  110. 110.
    Huncharek M. Brake mechanics, asbestos, and disease risk. Am J Forensic Med Pathol 1990; 11: 236–240.PubMedCrossRefGoogle Scholar
  111. 111.
    Begin R, Gauthier J, Desmeules M, Ostiguy G. Work-related mesothelioma in Quebec, 1967–1990. Am J Ind Med 1992; 22: 531–542.PubMedCrossRefGoogle Scholar
  112. 112.
    Hillerdal G. Malignant mesothelioma 1982: Review of 4710 published cases. Br J Dis Chest 1983; 77: 321–343.Google Scholar
  113. 113.
    Peterson JT, Jr., Greenberg SD, Buffler PA. Nonasbestos-related malignant mesothelioma: A review. Cancer (Philadelphia) 1984; 54: 951–960.CrossRefGoogle Scholar
  114. 114.
    Baris YI. Pleural mesotheliomas and abestos pleurisies due to environmental asbestos exposure in Turkey: An analysis of 120 cases. Hacettepe Bull Med/Surg 1975; 8: 165–185.Google Scholar
  115. 115.
    Baris YI, Sahin AA, Ozesmi M, et al. An outbreak of pleural mesothelioma and chronic fibrosing pleurisy in the village of Karain/Urgup in Anatolia. Thorax 1978; 33: 181–192.PubMedCrossRefGoogle Scholar
  116. 116.
    Artvinli M, Baris YI. Malignant mesotheliomas in a small village in the Anatolian region of Turkey: An epidemiologic study. J Natl Cancer Inst 1979; 63: 17–22.PubMedGoogle Scholar
  117. 117.
    Baris YI, Saracci R, Simonato L, SkidmoreJW, Artvinli M. Malignant mesothelioma and radiological chest abnormalities in two villages in central Turkey. Lancet 1981;i:984–987.Google Scholar
  118. 118.
    Artvinli M, Baris YI. Environmental fiber-induced pleuro-pulmonary diseases in an Anatolian village: An epidemiologic study. Arch Environ Health 1982; 37: 177–181.PubMedGoogle Scholar
  119. 119.
    Lillis R. Fibrous zeolites and endemic mesothelioma in Cappadocia, Turkey. J Occup Med 1981; 23: 548–550.Google Scholar
  120. 120.
    Sebastien P, Gaudichet A, Bignon J, Baris YI. Zeolite bodies in human lungs from Turkey. Lab Invest 1981; 44: 420–425.PubMedGoogle Scholar
  121. 121.
    Wagner JC, Skidmore JW, Hill RJ, Griffiths DM. Erionite exposure and mesotheliomas in rats. Br J Cancer 1985; 51: 727–750.PubMedCrossRefGoogle Scholar
  122. 122.
    Rohl AN, Langer AM, Moncure G, Selikoff IJ, Fischbein A. Endemic pleural disease associated with exposure to mixed fibrous dust in Turkey. Science 1982; 216: 518–520.PubMedCrossRefGoogle Scholar
  123. 123.
    Hillerdal G, Berg J. Malignant mesothelioma secondary to chronic inflammation and old scars: Two new cases and review of the literature. Cancer (Philadelphia) 1985; 55: 1968–1972.CrossRefGoogle Scholar
  124. 124.
    Austin MB, Fechner RE, Roggli VL. Pleural malignant mesothelioma following Wilms’ tumor. Am J Clin Pathol 1986; 86: 227–230.PubMedGoogle Scholar
  125. 125.
    Anderson KA, Hurley WC, Hurley BT, Ohrt DW. Malignant pleural mesothelioma following radiotherapy in a 16-year-old boy. Cancer (Philadelphia) 1985; 56: 273–276.CrossRefGoogle Scholar
  126. 126.
    Talerman A, Montero JR, Chilcote RR, Okagaki T. Diffuse malignant peritoneal mesothelioma in a 13year-old girl: Report of a case and review of the literature. Am J Surg Pathol 1985; 9: 73–80.PubMedCrossRefGoogle Scholar
  127. 127.
    Fraire AE, Cooper S, Greenberg SD, Buffler PA, Langston C. Mesothelioma of childhood. Lab Invest 1987; 56: 25A.Google Scholar
  128. 128.
    Fraire AE, Cooper S, Greenberg SD, Buffler P, Langston C. Mesothelioma of childhood. Cancer (Philadelphia) 1988; 62: 838–847.CrossRefGoogle Scholar
  129. 129.
    Lin-Chu M, Lee Y, Ho MY. Malignant mesothelioma in infancy. Arch Pathol Lab Med 1989; 113: 409–411.PubMedGoogle Scholar
  130. 130.
    Lynch HT, Katz D, Markvicka SE. Familial mesothelioma: review and family study. Cancer Genet Cytogenet 1985; 15: 25–35.PubMedCrossRefGoogle Scholar
  131. 131.
    Martensson G, Larsson S, Zettergren L. Malignant mesothelioma in two pairs of siblings: Is there a hereditary predisposing factor? Eur J Respir Dis 1984; 65: 179–184.PubMedGoogle Scholar
  132. 132.
    Hammar S. Familial mesothelioma: A report of two families. Hum Pathol 1989; 20: 107–112.PubMedCrossRefGoogle Scholar
  133. 133.
    Maolli PA, Macdonald JL, Goodglick LA, Kane AB. Acute injury and regeneration of the mesothelium in response to asbestos fibers. Am J Pathol 1987; 128: 426445.Google Scholar
  134. 133a.
    Adamson IYR, Bakowska J, Bowden DH. Mesothelial cell proliferation after instillation of long or short asbestos fibers into mouse lung. Am J Pathol 1993; 142: 1209–1216.PubMedGoogle Scholar
  135. 134.
    Muscat JE, Wynder EL. Cigarette smoking, asbestos exposure, and malignant mesothelioma. Cancer Res 1991; 51: 2263–2267.PubMedGoogle Scholar
  136. 135.
    Roggli VL, McGavran MH, Subach J, Sybers HD, Greenberg SD. Pulmonary asbestos body counts and electron probe analysis of asbestos body cores in patients with mesothelioma: A study of 25 cases. Cancer (Philadelphia) 1982; 50: 2423–2432.Google Scholar
  137. 136.
    Tuomi T, Huuskonen MS, Tammilehto L, Vanhala E, Virtamo M. Occupational exposure to asbestos evaluated from work histories and analysis of lung tissues from patients with mesothelioma. Br J Ind Med 1991; 48: 48–52.PubMedGoogle Scholar
  138. 137.
    Leigh J, Rogers AJ, Ferguson DA, Mudler HB, Ackad M, Thompson R. Lung asbestos fiber content and mesothelioma cell type, site and survival. Cancer (Philadelphia) 1991; 68: 135–141.CrossRefGoogle Scholar
  139. 137a.
    Roggli VL, Pratt PC, Brody AR. Asbestos fiber type in malignant mesothelioma: An analytical scanning electron microscopic study of 94 cases. Am J Ind Med 1993; 23: 605–614.PubMedCrossRefGoogle Scholar
  140. 138.
    McCaughey WTE. Criteria for the diagnosis of diffuse mesothelial tumors. Ann NY Acad Sci 1965; 132: 603613.Google Scholar
  141. 139.
    Kannerstein M, McCaughey WTE, Churg J, Selikoff IJ. A critique for the diagnosis of diffuse malignant mesothelioma. Mt Sinai J Med (NY) 1977; 44: 485–494.Google Scholar
  142. 140.
    Kannerstein M, Churg J, McCaughey WTE. Asbestos and mesothelioma: a review. Pathol Annu 1978: 81130.Google Scholar
  143. 141.
    Adams VI, Unni KK. Diffuse malignant mesothelioma of pleura: Diagnostic criteria based on an autopsy study. Am J Clin Pathol 1984; 82: 15–23.PubMedGoogle Scholar
  144. 142.
    McCaughey WTE, Kannerstein M, Churg J. Tumors and pseudotumors of the serous membranes. Washington, DC: Armed Forces Institute of Pathology, 1985.Google Scholar
  145. 143.
    Yousem SA, Hochholzer L. Malignant mesotheliomas with osseous and cartilaginous differentiation. Arch Pathol Lab Med 1987; 111: 62–66.PubMedGoogle Scholar
  146. 144.
    Kannerstein M, Churg J. Desmoplastic diffuse malignant mesothelioma. In: Fernoglio CM, Wolff M, eds. Progress in surgical pathology. New York: Masson, 1980: 19–29.Google Scholar
  147. 145.
    Cantin R, Al-Jabi M, McCaughey WTE. Desmoplastic diffuse mesothelioma. Am J Surg Pathol 1982; 6: 215222.Google Scholar
  148. 146.
    Dardick I, Al-Jabi M, McCaughey WTE, Srigley JR, van Nostrand AWP, Ritchie AC. Ultrastructure of poorly differentiated diffuse epithelial mesotheliomas. Ultrastruct Pathol 1984; 7: 151–160.PubMedCrossRefGoogle Scholar
  149. 147.
    Henderson DW, Atwood HD, Constance TJ, Shilkin KB, Steele RH. Lymphohistiocytoid mesothelioma: A rare variant of predominantly sarcomatoid mesothelioma. Ultra Pathology 1988; 12: 367–384.CrossRefGoogle Scholar
  150. 148.
    Whitaker D, Henderson DW, Shilkin KB. The concept of mesothelioma in situ: Implications for diagnosis and histogenesis. Semin Diagn Pathol 1992; 98: 151–161.Google Scholar
  151. 149.
    Myer J, Tazelaar H, Katzenstein L, et al. Localized malignant epithelioid and biphasic mesothelioma of the pleura: Clinicopathologic, immunohistochemical, and flow cytometric analysis of 3 cases. Mod Pathol 1992; 5: 679 (abstr).Google Scholar
  152. 150.
    Briselli M, Mark EJ, Dickersin GR. Solitary. fibrous tumors of the pleura: Eight new cases and review of 360 cases in the literature. Cancer (Philadelphia) 1981; 47: 2678–2689.CrossRefGoogle Scholar
  153. 151.
    Doucet J, Dardick I, Srigley JR, van Nostrand AWP, Bell MA, Kahn HJ. Localized fibrous tumour of serosal surfaces: Immunohistochemical and ultrastructural evidence for a type of mesothelioma. Virchows Arch [Pathol Anat] 1986; 409: 349–3653.CrossRefGoogle Scholar
  154. 152.
    Carter D, Otis CN. Three types of spindle cell tumors of the pleura: fibroma, sarcoma and sarcomatoid mesothelioma. Am J Surg Pathol 1988; 12: 747–753.PubMedCrossRefGoogle Scholar
  155. 153.
    England DM, Hochholzer L, McCarthy MJ. Localized benign and malignant fibrous tumors of the pleura: A clinicopathologic review of 223 cases. Am J Surg Pathol 1989; 13: 640–658.CrossRefGoogle Scholar
  156. 154.
    Cook HG, Carbohydrates. In: Bancroft JD, Stevens A, eds. Theory and practice of histological techniques. New York: Churchill Livingstone, 1982: 180–216.Google Scholar
  157. 155.
    Ernst CS, Atkinson BF. Mucicarmine positivity in malignant mesothelioma. Lab Invest 1980; 42: 113–114 (abstr).Google Scholar
  158. 156.
    McCaughey WTE, Colby TV, Battifora H, et al. Diagnosis of diffuse malignant mesothelioma: Experience of a US/Canadian mesothelioma panel. Mod Pathol 1991; 4: 342–353.PubMedGoogle Scholar
  159. 157.
    MacDougall D, Wang SE, Zidar BL. Mucin-positive epithelial mesothelioma. Arch Pathol Lab Med 1992; 116: 874–880.PubMedGoogle Scholar
  160. 158.
    Hammar SP, Bockus DE, Remington FL, Rohrbach KA. Mucicarmine positive mesothelioma: A histochemical, immunohistochemical, and ultrastructural comparison with micin-producing pulmonary adenocarcinoma (submitted to Ultra Pathol).Google Scholar
  161. 159.
    Benjamin CJ, Ritchie AC. Histological staining for the diagnosis of mesothelioma. Am J Med Technol 1982; 48: 905–908.PubMedGoogle Scholar
  162. 160.
    Hsu SM, Raine L, Fanger H. Use of avidin-biotin peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 577–580.PubMedCrossRefGoogle Scholar
  163. 161.
    Sun TT, Eichner R, Nelson WG, et al. Keratin classes: Molecular markers for different types of epithelial differentiation. J Invest Dermatol 1983; 81: 109–115 (suppl).Google Scholar
  164. 162.
    Moll R, Franke WW, Schiller DL, et al. The catalogue of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31: 1124.CrossRefGoogle Scholar
  165. 163.
    Bolen JW, Hammar SP, McNutt MA. Reactive and neoplastic serosal tissue: A light-microscopic, ultra-structural and immunocytochemical study. Am J Surg Pathol 1986; 10: 34–47.PubMedCrossRefGoogle Scholar
  166. 164.
    Montag AG, Pinkus GS, Coson JM. Immunoreactivity for keratin proteins in sarcomatoid diffuse malignant mesothelioma: A diagnostic discriminant among spindle cell tumors. Lab Invest 1985; 52: 44A.Google Scholar
  167. 165.
    Leong AS-Y, Parkinson R, Milios J. “Thick” cell membranes revealed by immunocytochemical staining: A clue to the diagnosis of mesothelioma. Diagn Cytopathol 1990; 6: 9–13.Google Scholar
  168. 166.
    Miettinen M. Keratin subsets in spindle cell sarcomas: Keratins are widespread but synovial sarcoma contains a distinctive keratin polypeptide pattern and desmoplakins. Am J Pathol 1991; 138: 505–513.PubMedGoogle Scholar
  169. 167.
    Said JW, Nash G, Banks-Schlegel S, Sassoon AF, Shintaku IF. Keratin in human lung tumors: Patterns of localization of different molecular-weight keratin proteins. Am J Pathol 1983; 113: 27–32.PubMedGoogle Scholar
  170. 168.
    Watts AE, Said JW, Shintaku IP, Sassoon AF, Banks-Schlegel S. Keratins of different molecular weight in exfoliated mesothelial and adenocarcinoma cells-an aid to cell identification. Am J Clin Pathol 1984; 81: 442–446.Google Scholar
  171. 169.
    Kahn HJ, Hanna W, Yeger H, Baumal R. Immunohistochemical localization of prekeratin filaments in benign and malignant cells in effusions: Comparison with intermediate filament distribution by electromicroscopy. Am J Pathol 1982; 109: 206–214.PubMedGoogle Scholar
  172. 170.
    Kahn HJ, Thorner PS, Yeger H, Bailey D, Baumal R. Distinct keratin patterns demonstrated by immunoperoxidase staining of adenocarcinomas, carcinoids and mesotheliomas using polyclonal and monoclonal anti-keratin antibodies. Am J Clin Pathol 1986; 86: 566–574.PubMedGoogle Scholar
  173. 171.
    Blobel GA, Moll R, Franke WW, Kayser KW, Gould VE. The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol 1985; 121: 235–247.PubMedGoogle Scholar
  174. 172.
    Moll R, Dhovailly D, Sun T. Expression of keratin 5 as a distinctive feature of epithelial and biphasic mesotheliomas: An immunohistochemical study using monoclonal antibody AE14. Virchow Arch [B] Cell Pathol 1989; 58: 129–145.CrossRefGoogle Scholar
  175. 173.
    Churg A. Immunohistochemical staining for vimentin and keratin in malignant mesothelioma. Am J Surg Pathol 1985; 9: 360–365.PubMedCrossRefGoogle Scholar
  176. 174.
    Jasani B, Edwards RE, Thomas ND, Gibbs AR. The use of vimentin antibodies in the diagnosis of malignant mesothelioma. Virchows Arch [A] 1985; 406: 441–448.CrossRefGoogle Scholar
  177. 175.
    Mullink H, Henzen-Logmans SC, Alons-van Kordelaar JJM, et al. Simultaneous immunoenzyme staining of vimentin and cytokeratins with monoclonal antibodies as an aid in the differential diagnosis of malignant mesothelioma from pulmonary adenocarcinoma. Virchows Arch [B] Pathol Anat 1986; 42: 55–65.Google Scholar
  178. 176.
    Upton MP, Hirohashi S, Tome Y, Miyazawa N, Suemasu K, Shimosato Y. Expression of vimentin in surgically resected adenocarcinomas and large cell carcinomas of lung. Am J Surg Pathol 1986; 10: 560–567.PubMedCrossRefGoogle Scholar
  179. 177.
    Marshall RJ, Herbert A, Braye SG, Jones DB. Use of antibodies to carcinoembryonic antigen and human milk fat globule to distinguish carcinoma, mesothe-lioma and reactive mesothelium. J Clin Pathol 1984; 37: 1215–1221.PubMedCrossRefGoogle Scholar
  180. 178.
    Loosli H, Hurlimann J. Immunohistological study of malignant diffuse mesotheliomas of the pleura. Histopathology 1984; 8: 793–803.PubMedCrossRefGoogle Scholar
  181. 179.
    Hammar SP, Bolen J W, Bockus D, Remington F, Friedman S. Ultrastructural and immunohistochemical features of common lung tumors: An overview. Ultra Pathol 1985; 9: 283–318.Google Scholar
  182. 180.
    Battifora H, Kopinski MI. Distinction of mesothelioma from adenocarcinoma: An immunohistochemical approach. Cancer (Philadelphia) 1985; 55: 1679–1685.CrossRefGoogle Scholar
  183. 181.
    Wang N-S, Huang S-N, Gold P. Absense of carcinoembryonic antigen-like material in mesothelioma: An immunohistochemical differentiation from lung cancer. Cancer (Philadelphia) 1979; 44: 947–954.Google Scholar
  184. 182.
    Whitaker D, Shilkin KB. Carcinoembryonic antigen in tissue diagnosis of malignant mesothelioma. Lancet 1981;i:1369.Google Scholar
  185. 183.
    Corson JM, Pinkus GS. Mesothelioma: Profile of keratin proteins and carcinoembryonic antigen: An immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas. Am J Pathol 1982; 108: 80–87.PubMedGoogle Scholar
  186. 184.
    Kwee WS, Veldhuizen RW, Golding RP, et al. Histologic distinction between malignant mesothelioma, benign pleural lesion and carcinoma metastasis: Evaluation of the application of morphometry combined with histochemistry and immunostaining. Virchows Arch [A] 1982; 397: 287–299.CrossRefGoogle Scholar
  187. 185.
    Said JW, Nash G, Tepper G, Banks-Schlegel S. Keratin proteins and carcinoembryonic antigen in lung carcinoma: An immunoperoxidase study of fifty-four cases with ultrastructural correlations. Hum Pathol 1983; 14: 70–76.CrossRefGoogle Scholar
  188. 186.
    Ghosh AK, Spriggs AL, Taylor-Papadimitriou J, Mason DY. Immunocytochemical staining of cells in pleural and peritoneal effusions with a panel of monoclonal antibodies. J Clin Pathol 1983; 36: 1154–1164.PubMedCrossRefGoogle Scholar
  189. 187.
    Holden J, Churg A. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma. Am J Surg Pathol 1984; 8: 277–279.PubMedCrossRefGoogle Scholar
  190. 188.
    Lee I, Radosevich JA, Chejfec G, et al. Malignant mesotheliomas: Improved differential diagnosis from lung adenocarcinomas using monoclonal antibodies 44–3A6 and 624Al2. Am J Pathol 1986; 123: 497–507.PubMedGoogle Scholar
  191. 189.
    Sheibani K, Battifora H, Burke JS. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas: An immunohistologic analysis demonstrating the value of Leu M1 antigen. Am J Pathol 1986; 123: 212–219.PubMedGoogle Scholar
  192. 190.
    Szpak CA, Johnston WW, Roggli V, et al. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). Am J pathol 1986; 122: 252–260.PubMedGoogle Scholar
  193. 191.
    Metzger J, Lamerz R, Permanether W. Diagnostic significance of carcinoembryonic antigen in the differen-tial diagnosis of malignant mesothelioma. J Thorac Cardiovasc Surg 1990; 100: 860–866.Google Scholar
  194. 192.
    Sheibani K, Battifora H. Leu-M 1 positivity not specific for Hodgkin’s disease. Am J Clin Pathol 1985; 84: 682.PubMedGoogle Scholar
  195. 193.
    Sheibani K, Battifora H, Burke JS, et al. Leu-M 1 in human neoplasms: An immunohistologic study of 400 cases. Am J Surg Pathol 1986; 10: 227–236.PubMedCrossRefGoogle Scholar
  196. 194.
    Sheibani K, Battifora H, Burke J. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas: An immunohistologic analysis demonstrating the value of Leu M 1 antigen. Am J Pathol 1986; 123: 212–219.Google Scholar
  197. 195.
    Sheibani K, Azumi N, Battifora H. Further evidence demonstrating the value of Leu-M 1 antigen in differential diagnosis of malignant mesothelioma and adenocarcinoma: an immunohistologic evaluation of 395 cases. Lab Invest 1988; 58: 84A.Google Scholar
  198. 196.
    Otis CN, Carter D, Cole S, Battifora H. Immunohistochemical evaluation of pleural mesothelioma and pulmonary adenocarcinoma. Am J Surg Pathol 1987; 11: 445–456.PubMedCrossRefGoogle Scholar
  199. 197.
    Sheibani K, Shin SS, Kezirian J, Weiss LM. Ber-EP4 antibody as a discriminant in the differential diagnosis of malignant mesothelioma. J Thorac Cardiovasc Surg 1990; 100: 860–866.Google Scholar
  200. 198.
    Goffey MJ, Mills SE, Swanson PE, Zarbo RJ, Shah AR, Wick MR. Immunoreactivity for BER-EP4 in adenocarcinomas, adenomatoid tumors, and malignant mesotheliomas. Am J Surg Pathol 1992; 16: 593–599.CrossRefGoogle Scholar
  201. 199.
    Radosevich JA, Ma Y, Lee I, et al. Monoclonal antibody 44–3A6 in cell blocks in the diagnosis of lung carcinoma, carcinomas metastatic to lung and pleura, and pleural malignant mesotheliomas. Am J Clin Pathol 1991; 95: 322–329.PubMedGoogle Scholar
  202. 200.
    Spagnolo DV, Whitaker D, Carrello S, Radosevich JA, Rosen ST, Gould VE. The use of monoclonal antibody 44–3A6 in cell blocks in the diagnosis of lung carcinoma, carcinomas metastatic to lung and pleura, and pleural malignant mesothelioma. Am J Clin Pathol 1991; 95: 322–329.PubMedGoogle Scholar
  203. 201.
    Collins CL, Ordones NG, Schaefer R, et al. Thrombomodulin expression in malignant pleural mesothelioma and pulmonary adenocarcinoma. Am J Pathol 1992; 141: 827–833.PubMedGoogle Scholar
  204. 202.
    Jordan D, Jagurdar J, Kanedo M. Blood group antigens, Lewis“ and Lewisy in the diagnostic discrimination of malignant mesothelioma versus adenocarcinoma. Am J Pathol 1989; 134: 931–937.Google Scholar
  205. 203.
    Noguchi M, Nakajima T, Hirohashi S, Akiba T, Shimosato Y. Immunohistochemical distinction of malignant mesothelioma from pulmonary adenocarcinoma with anti-surfactant apoprotein, anti-Lewisa, and anti-Tn antibodies. Hum Pathol 1989; 20: 53–57.PubMedCrossRefGoogle Scholar
  206. 204.
    Kawai T, Suzuki M, Torikata C, Suzuki Y. Expression of blood group-related antigens and helix promatia agglutinin in malignant pleural mesothelioma and pulmonary adenocarcinoma. Hum Pathol 1991; 22: 118124.Google Scholar
  207. 205.
    Wick MR, Mills SE, Swanson PE. Expression of “my-elomonocytic” antigens in mesotheliomas and adenocarcinomas involving the serosal surfaces. Am J Clin Pathol 1990; 94: 18–26.PubMedGoogle Scholar
  208. 206.
    Azumi N, Underhill CB, Kagan E, Sheibani K. A novel biotinylated probe specific for hyaluronate: Its diagnostic value in diffuse malignant mesothelioma. Am J Surg Pathol 1992; 16: 116–121.PubMedCrossRefGoogle Scholar
  209. 207.
    O’Hara CJ, Corson JM, Pinkus GS, Stahel RA. ME1: A monoclonal antibody that distinguishes epithelial-type malignant mesothelioma from pulmonary adenocarcinoma and extrapulmonary malignancies. Am J Pathol 1990; 136: 421–428.PubMedGoogle Scholar
  210. 208.
    Sheibani K, Esteban JM, Bailey A, Battifora H, Weiss LM. Immunopathologic and molecular studies as an aid to the diagnosis of malignant mesothelioma. Hum Pathol 1992; 23: 107–116.PubMedCrossRefGoogle Scholar
  211. 209.
    Okamoto H, Matsuno Y, Noguchi M, et al. Malignant pleural mesothelioma producing chorionic gonadotropin: report of two cases. Am J Surg Pathol 1992; 16: 969–974.PubMedCrossRefGoogle Scholar
  212. 210.
    McAuley P, Asa SL, Chiu B, Henderson J, Goltzman D, Drucker DJ. Parathyroid hormone-like peptide in normal and neoplastic mesothelial cells. Cancer (Philadelphia) 1990; 66: 1975–1979.CrossRefGoogle Scholar
  213. 211.
    Warnock ML, Stoloff A, Thor A. Differentiation of adenocarcinoma of the lung from mesothelioma: periodic acid-Schiff, monoclonal antibodies B72.3 and Leu M 1. Am J Pathol 1988; 133: 30–38.PubMedGoogle Scholar
  214. 212.
    Khoury N, Raju U, Crissman JD, Zarbo RJ, Greenawald KA. A comparative immunohistochemical study of peritoneal and ovarian serous tumors, and mesotheliomas. Hum Pathol 1990; 21: 811–819.PubMedCrossRefGoogle Scholar
  215. 213.
    Wick MR, Loy T, Mills SE, Legier JF, Manivel JC. Malignant epithelioid pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural and immunohistologic study of 103 cases. Hum Pathol 1990; 21: 759–766.PubMedCrossRefGoogle Scholar
  216. 214.
    Wirth PR, Legier J, Wright GL. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma. Cancer (Philadelphia) 1991; 67: 655–662.CrossRefGoogle Scholar
  217. 215.
    Soosay GN, Griffiths M, Papadaki L, Happerfield L, Borrow L. The differential diagnosis of epithelial mesothelioma from adenocarcinoma and reactive mesothelial proliferation. J Pathol 1991; 163: 299–305.PubMedCrossRefGoogle Scholar
  218. 216.
    Esteban JM, Yokota S, Husain S, Battifora H. Immunocytochemical profile of benign and carcinomatous effusions: A practical approach to difficult diagnosis. Am J Clin Pathol 1990; 94: 698–705.PubMedGoogle Scholar
  219. 217.
    Tickmon RJ, Cohen C, Varma VA, Fekete PS, De Rose PB. Distinction between carcinoma cells and mesothelial cells in serous effusions: Usefulness of immunohistochemistry. Acta Cytol 1990; 34: 491–496.Google Scholar
  220. 218.
    Nance KV, Silverman JF. Immunocytochemical panel for the identification of malignant cells in serous effusions. Am J Clin Pathol 1991; 95: 867–874.PubMedGoogle Scholar
  221. 219.
    Kuhlman L, Berghäuser K-H, Schäffer R. Distinction of mesothelioma from carcinoma in pleural effusions: An immunocytochemical study on routinely processed cytoblock preparations. Pathol Res Pract 1991; 187: 467–471.CrossRefGoogle Scholar
  222. 220.
    Cibas ES, Corson JM, Pinkus GS. The distinction of adenocarcinoma from malignant mesothelioma in cell blocks of effusions: The role of routine mucin histochemistry and immunohistochemical assessment of carcinoembryonic antigen, keratin proteins, epithelial membrane antigen, and milk fat globule-derived antigen. Hum Pathol 1987; 18: 67–74.PubMedCrossRefGoogle Scholar
  223. 221.
    Suzuki Y, Churg J, Kannerstein M. Ultrastructure of human malignant diffuse mesothelioma. Am J Pathol 1976; 85: 241–262.PubMedGoogle Scholar
  224. 222.
    Stoebner P, Bernaudin JF, Nebut M, Basset F. Contribution of electron microscopy to the diagnosis of pleural mesothelioma. Ann NY Acad Sci 1979; 330: 75 1760.Google Scholar
  225. 223.
    Kay S, Silvergerg SG. Ultrastructural studies of a malignant fibrous mesothelioma of the pleura. Arch Pathol Lab Med 1971; 92: 449–455.Google Scholar
  226. 224.
    Wang N-S. Electron microscopy in the diagnosis of pleural mesotheliomas. Cancer (Philadelphia) 1973; 31: 1046–1054.CrossRefGoogle Scholar
  227. 225.
    Bolen JW, Thorning D. Mesotheliomas. A light and electron-microscopical study concerning histogenetic relationships between the epithelial and mesenchymal variants. Am J Surg Pathol 1980; 4: 451–464.PubMedCrossRefGoogle Scholar
  228. 226.
    Klima M, Bossart MI. Sarcomatous type of malignant mesothelioma. Ultrastruct Pathol 1983; 4: 349–358.PubMedCrossRefGoogle Scholar
  229. 227.
    d’Andiran G, Gabbiani G. A metastasing sarcoma of the pleura composed of myofibroblasts. In: Fenoglio CM, Wolff M, eds. Progress in surgical pathology. New York: Mason, 1980: 31–40.Google Scholar
  230. 228.
    Epstein JI, Budin RE. Keratin and epithelial membrane antigen immunoreactivity in nonneoplastic fibrous pleural lesions: Implications for the diagnosis of desmoplastic mesothelioma. Hum Pathol 1986; 17: 514–519.Google Scholar
  231. 229.
    Erlandson RA, Cordon-Cardo C, Melamed MR. Proposed classification of pleural neoplasms. Lab Invest 1986; 54: 19A.Google Scholar
  232. 230.
    el-Naggar A, Ward RM, Ro JY, Ayala AG, Ordonez NG. Fibrous tumor with hemangiopericytic pattern, so called “localized fibrous tumor of pleura. ” Lab Invest 1987; 56: 21A.Google Scholar
  233. 231.
    Warhol MJ, Hickey WF, Corson JM. Malignant mesothelioma: Ultrastructural distinction from adenocarcinoma. Am J Surg Pathol 1982; 6: 307–314.PubMedCrossRefGoogle Scholar
  234. 232.
    Warhol MJ, Corson JM. An ultrastructural comparison of mesotheliomas with adenocarcinomas of the lung and breast. Hum Pathol 1985; 16: 50–55.PubMedCrossRefGoogle Scholar
  235. 233.
    Burns TR, Greenberg SD, Mace ML, Johnson EH. Ultrastructural diagnosis of epithelial malignant mesothelioma. Cancer (Philadelphia) 1985; 56: 2036 2040.Google Scholar
  236. 234.
    Burns TRI, Johnson EH, Cartwright J, Jr., Greenberg SD. Desmosomes of epithelial malignant mesothelioma. Ultra Pathol 1988; 12: 385–388.CrossRefGoogle Scholar
  237. 235.
    Tiainen M, Tammilethol L, Rautonen J, Tumoi T, Mattson K, Knoutila S. Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. Br J Cancer 1989; 60: 618–626.PubMedCrossRefGoogle Scholar
  238. 236.
    Hagemeijer A, Versnel MA, Van Drunen E, Moret M, Bouts MJ, van der Kwast TH, Hoogsteden HC. Cytogenetic analysis of malignant mesothelioma. Cancer Genet Cytogenet 1990; 47: 1–28.PubMedCrossRefGoogle Scholar
  239. 237.
    Croonen AM, van der Valk P, Herman CJ, Lindeman J. Cytology, immunopathology and flow cytometry in the diagnosis of pleural and peritoneal effusions. Lab Invest 1988; 58: 725–732.PubMedGoogle Scholar
  240. 238.
    Hafiz MA, Becker RL Jr, Mikel UV, Bahr GE. Cytophotometric determination of DNA in mesotheliomas and reactive mesothelial cells. Anal Quant Cytol Histol 1988; 58: 120–126.Google Scholar
  241. 239.
    Frierson HF, Mills SE, Legier JF. Flow cytometric analysis of ploidy in immunohistochemically confirmed examples of malignant mesothelioma. Am J Clin Pathol 1988; 90: 240–243.PubMedGoogle Scholar
  242. 240.
    Burmer GC, Rabinovitch PS, Kulander BG, Rusch V, McNutt MA. Flow cytometric analysis of malignant pleural mesothelioma: relationship to histology and survival. Hum Pathol 1989; 20: 777–783.PubMedCrossRefGoogle Scholar
  243. 241.
    Dazzi H, Thatcher N, Hasleton PS, Chattlerjee AK, Lawson AM. DNA analysis by flow cytometry in malignant pleural mesothelioma: Relationship to histology and survival. J Pathol 1990; 162: 51–55.PubMedCrossRefGoogle Scholar
  244. 242.
    Tierney G, Wilkinson MJ, Jones JSP. The malignancy grading method is not a reliable assessment of malignancy in mesothelioma. J Pathol 1990; 160: 209–211.PubMedCrossRefGoogle Scholar
  245. 243.
    El-Naggar AK, Ordone NG, Garnsey L, Batsakis JG. Epithelioid pleural mesotheliomas and pulmonary adenocarcinomas: A comparative DNA flow cytometric study. Hum Pathol 1991; 22: 972–978.PubMedCrossRefGoogle Scholar
  246. 244.
    Esteban JM, Sheibani K. DNA ploidy analysis of pleural mesotheliomas: Its usefulness for their distinction from lung adenocarcinomas. Mod Pathol 1992; 6: 626630.Google Scholar
  247. 245.
    Raftery AT. Regeneration of parietal and visceral peritoneum. An electron microscopical study. J Anat 1973; 115: 375–392.PubMedGoogle Scholar
  248. 246.
    Schurch W, Seemayer TA, Legace R, Gabbiani G. Intermediate filament cytoskeleton of myofibroblasts: An immunofluorescence and ultrastructural study. Lab Invest 1984; 50: 52A.Google Scholar
  249. 247.
    Majno G. The story of the myofibroblast. Am J Surg Pathol 1979; 3: 535–542.PubMedCrossRefGoogle Scholar
  250. 248.
    Davila RM, Couch EC. The role of mesothelial and submesothelial stromal cells in matrix remodeling following pleural injury. Am J Pathol 1993; 142: 547–555.PubMedGoogle Scholar
  251. 249.
    Roberts GH. Diffuse pleural mesothelioma. A clinical and pathological study. Br J Dis Chest 1970; 64: 20 1211.Google Scholar
  252. 250.
    O’Donnell WM, Mann RH, Grosh JL. Asbestos, an extrinsic factor in the pathogenesis of bronchogenic carcinoma and mesothelioma. Cancer (Philadelphia) 1966; 19: 1143–1148.CrossRefGoogle Scholar
  253. 251.
    Chernow B, Sahn SA. Carcinomatous involvement of the pleura: An analysis of 96 patients. Am J Med 1977; 63: 695–702.PubMedCrossRefGoogle Scholar
  254. 252.
    Babolini G, Blasi A. The pleural form of primary cancer of the lung. Dis Chest 1956; 29: 314–323.PubMedCrossRefGoogle Scholar
  255. 253.
    Harwood TR, Gracey DR, Yokoo H. Pseudomesotheliomatous carcinoma of the lung: A variant of peripheral lung cancer. Am J Clin Pathol 1976; 65: 159–167.PubMedGoogle Scholar
  256. 254.
    McCaughey WTE, Dardick I, Barr RJ. Angiosarcomas of serous membranes. Arch Pathol Lab Med 1983; 107: 304–307.PubMedGoogle Scholar
  257. 255.
    Willen R, Bruce T, Dahlstrom G, Dubiel WT. Squamous epithelial cancer in metaplastic pleura following extrapleural pneumothorax for pulmonary tuberculosis. Virchows Arch [A] 1976; 370: 225–231.CrossRefGoogle Scholar
  258. 256.
    Crome L. Squamous metaplasia of the peritoneum. J Pathol Bacteriol 1950; 62: 61–68.PubMedCrossRefGoogle Scholar
  259. 257.
    Kwee WS, Veldhuizen RW, Golding RP, Donner R. Primary “adenosquamous” mesothelioma of the pleura. Virchows Arch [A] 1981; 393: 353–357.CrossRefGoogle Scholar
  260. 258.
    Falor WH, Ward RM, Brezler MR. Diagnosis of pleural effusions by chromosome analysis. Chest 1982; 81: 193197.Google Scholar
  261. 259.
    Henderson DW, Whitaker D, Shilkin KB. The differential diagnosis of malignant mesothelioma: A practical approach to diagnosis during life. In: Henderson DW, Shilkin KB, Langlois SLP, Whitaker D, eds. Malignant Mesothelioma, New York, Hemisphere, 1992; 184.Google Scholar
  262. 260.
    Friman C, Hellström PE, Juvani M, Riska H. Acid glycosaminoglycans (mucopolysaccharides) in the differential diagnosis of pleural effusion. Clin Chim Acta 1977; 76: 357–361.PubMedCrossRefGoogle Scholar
  263. 261.
    Arai H, Kang K, Sato H, et al. Significance of the quantification and demonstration of hyaluronic acid in tissue specimens for the diagnosis of pleural mesothelioma. Am Rev Respir Dis 1979; 120: 529–532.PubMedGoogle Scholar
  264. 262.
    Castor CW, Naylor B. Acid mucopolysaccharide composition of serous effusions. Cancer (Philadelphia) 1967; 20: 462–466.CrossRefGoogle Scholar
  265. 263.
    Rasmussen KN, Faber V. Hyaluronic acid in 247 pleural fluids. Scand J Respir Dis 1967; 48: 366–371.Google Scholar
  266. 264.
    Thompson ME, Bromberg PA, Amenta JS. Acid muco-polysaccharide determination: A useful adjunct for the diagnosis of malignant mesothelioma with effusion. Am J Clin Pathol 1969; 52: 335–339.PubMedGoogle Scholar
  267. 265.
    Pettersson T, Fröseth B, Rista H, Klockars M. Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest 1988; 94: 1037–1039.PubMedCrossRefGoogle Scholar
  268. 266.
    Hillerdal G, Lindqvist U, Engström-Laurent A. Hyaluronan in pleural effusions and in serum. Cancer (Philadelphia) 1991; 67: 2410–2414.CrossRefGoogle Scholar
  269. 267.
    Chiu B, Churg A, Tengblad A, Pearce R, McCaughey WTE. Analysis of hyaluronic acid in the diagnosis of malignant mesothelioma. Cancer (Philadelphia) 1984; 54: 2195–2199.CrossRefGoogle Scholar
  270. 268.
    Nakano T, Fujii J, Tamura S, et al. Glycosaminoglycan in malignant pleural mesothelioma. Cancer (Philadelphia) 1986; 57: 106–110.CrossRefGoogle Scholar
  271. 269.
    Iozzo RV. Biology of disease. Proteoglycans: structure, function and role in neoplasia. Lab Invest 1985; 53: 373–396.PubMedGoogle Scholar
  272. 270.
    Iozzo RV, Goldes JA, Chen W J, Wight JN. Glycosaminoglycans of pleural mesothelioma: A possible biochemical variant containing chondroitin sulfate. Cancer (Philadelphia) 1981; 48: 89–97.CrossRefGoogle Scholar
  273. 271.
    Hammar SP. Mesothelioma. In: Sheppard MN, ed. Practical Pulmonary Pathology,Mill Road, Hodder & Stoughton, in press.Google Scholar
  274. 272.
    Antman KH. Current concepts: Malignant mesothelioma. N Engl J Med 1980; 303: 200–202.PubMedCrossRefGoogle Scholar
  275. 273.
    Butchart EG, Ashcroft T, Barnsley WC, Holden M. The role of surgery in diffuse malignant mesothelioma of the pleura. Semin Oncol 1981; 8: 321–328.PubMedGoogle Scholar
  276. 274.
    Roberts GH. Distant visceral metastases in pleural mesothelioma. Br J Dis Chest 1976; 70: 246–250.PubMedCrossRefGoogle Scholar
  277. 275.
    Elmes PC, Simpson MJC. The clinical aspects of mesothelioma. Quart J Med 1976; 45: 427–429.PubMedGoogle Scholar
  278. 276.
    Doward AJ, Stack BHR. Diffuse malignant pleural mesothelioma in Glasgow. Br J Dis Chest 1981; 75: 397–402.CrossRefGoogle Scholar
  279. 277.
    Roggli VL, McGavran MH, Subach J, Sybers HD, Greenberg SD. Pulmonary asbestos body counts and electron probe analysis of asbestos body cores in patients with mesothelioma. Cancer (Philadelphia) 1982; 50: 2423–2432.CrossRefGoogle Scholar
  280. 278.
    Chahiniart AP, Pajak TF, Holland JF, Norton L, Ambindar RM, Mandel EM. Diffuse malignant mesothelioma. Ann Intern Med 1982; 96: 746–755.CrossRefGoogle Scholar
  281. 279.
    Adams VI, Unni KK. Diffuse malignant mesothelioma of pleura: Diagnostic criteria based on an autopsy study. Am J Clin Pathol 1984; 82: 15–23.PubMedGoogle Scholar
  282. 280.
    Solomons K. Malignant mesothelioma-Clinical and epidemiological features. S Afr Med J 1984; 66: 407412.Google Scholar
  283. 281.
    Krumhaar D, Lange S, Hartman C, Anhuth D. Follow-up study of 100 malignant pleural mesotheliomas. Thorac Cardiovasc Surgeon 1985; 33: 272–275.CrossRefGoogle Scholar
  284. 282.
    Huncharek M, Muscat J. Metastases in diffuse pleural mesothelioma: Influence of histological type. Thorax 1987; 42: 897–898.Google Scholar
  285. 283.
    Hulks G, Thomas JSJ, Waclawski E. Malignant pleural mesothelioma in western Glasgow, 1980–1986. Thorax 1989; 44: 496–500.PubMedCrossRefGoogle Scholar
  286. 284.
    Sussman J, Rosai J. Lymph node metastasis as the initial manifestation of malignant mesothelioma: Report of six cases. Am J Surg Pathol 1990; 14: 819–828.Google Scholar
  287. 285.
    Case records of the Massachusetts General Hospital: Case 36–1990: N Engl J Med 1990; 323: 659–667.Google Scholar
  288. 286.
    Huncharek M, Smith K. Extrathoracic lymph node metastases in malignant pleural mesothelioma. Chest 1988; 93: 443–444.PubMedCrossRefGoogle Scholar
  289. 287.
    Kim SB, Varkey B, Choi H. Diagnosis of malignant pleural mesothelioma by axillary lymph node biopsy. Chest 1986; 91: 279–281.CrossRefGoogle Scholar
  290. 288.
    Uri AJ, Schulman ES, Steiner RM, Scott RD, Rose LJ. Diffuse contralateral pulmonary metastases in malignant mesothelioma: An unusual radiographic presentation. Chest 1988; 93: 433–434.PubMedCrossRefGoogle Scholar
  291. 289.
    Kaye JA, Wang A, Joachim CL, Seltzer SE, Cibas E, Skarin A, Antman KH. Malignant mesothelioma with brain metastases. Am J Med 1986; 80: 95–97.PubMedCrossRefGoogle Scholar
  292. 290.
    Sridkar RS, Hussein A, Ganjei P, et al. Brain metastases in malignant pleural mesotheliomas. Case report and review of the literature. Am J Clin Oncol 1989; 12: 22 2228.Google Scholar
  293. 291.
    Huncharek M, Muscat J. Cerebral metastases in pleural mesothelioma. Am J Clin Oncol 1990; 13: 180–181.PubMedCrossRefGoogle Scholar
  294. 292.
    Falconieri G, Grandi G, DiBonito L, Bonifacio-Gori D, Giarelli L. Intracranial metastases from malignant pleural mesothelioma: report of three autopsy cases and review of the literature. Arch Pathol Lab Med 1991; 115: 591–595.PubMedGoogle Scholar
  295. 293.
    Chen KTK. Malignant mesothelioma presenting as Sister Joseph’s nodule. Am J Dermatopathol 1991; 13: 300–303.PubMedCrossRefGoogle Scholar
  296. 294.
    Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin T, Canellos GP. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980; 68: 356–362.PubMedCrossRefGoogle Scholar
  297. 295.
    Chailleux E, Dabouis G, Pioche D, de Lajartre M, de Lajartre A-Y, Rembeaux A, Germaud P. Prognostic? factors in diffuse malignant pleural mesothelioma: a study of 167 patients. Chest 1988; 93: 159–162.PubMedCrossRefGoogle Scholar
  298. 296.
    Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dano-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades, 1965–1985. J Clin Oncol 1988; 6: 147–153.PubMedGoogle Scholar
  299. 297.
    Alberts AS, Falkson G, Goedhals L, Vorobiof DA, Van Dor Merwe CA. Malignant pleural mesotheliom: a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988; 6: 527–535.PubMedGoogle Scholar
  300. 298.
    Ruffle P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 322 patients. J Clin Oncol 1989; 7: 1157–1168.Google Scholar
  301. 299.
    Harvey JC, Fleischman EH, Kagan AR, Streeter 0E. Malignant pleural mesothelioma: a survival pleural mesothelioma: a survival study. J Surg Oncol 1990; 45: 40–42.PubMedCrossRefGoogle Scholar
  302. 300.
    Ribak J, Selikoff IJ. Survival of asbestos insulation workers with mesothelioma. Br J Ind Med 1992; 49: 732–735.PubMedGoogle Scholar
  303. 301.
    Tammilehto L. Malignant mesothelioma: Prognostic factors in a prospective study of 98 patients. Lung Cancer 1992; 8: 175–184.CrossRefGoogle Scholar
  304. 302.
    Sridhar KS, Doria R, Raub WA, Jr., Thurer RJ, Saldana M. New strategies are needed in diffuse malignant mesothelioma. Cancer (Philadelphia) 1992; 70: 2969–2979.CrossRefGoogle Scholar
  305. 303.
    Worn H. Moglichkeiten and Ergebnisse der chirugischen Behandlung des malignen Pleura mesothelioms. Thoraxchirurgie 1974; 22: 391–393.Google Scholar
  306. 304.
    Wanebo HJ, Martini N, Melamed MR, Hilaris B, Beattie EJ, Jr. Pleural mesothelioma. Cancer (Philadelphia) 1976; 38: 2481–2488.CrossRefGoogle Scholar
  307. 305.
    DeLaria GA, Jensik R, Faber P, Kittle F. Surgical management of malignant mesothelioma. Ann Thorac Surg 1978; 26: 375–382.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Samuel P. Hammar

There are no affiliations available

Personalised recommendations